Novel targeted siRNA-loaded hybrid nanoparticles: preparation, characterization and in vitro evaluation
Open Access
- 26 September 2015
- journal article
- research article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 13 (1) , 1-13
Abstract
SiRNAs have a high potential for silencing critical molecular pathways that are pathogenic. Nevertheless, their clinical application has been limited by a lack of effective and safe nanotechnology-based delivery system that allows a controlled and safe transfection to cytosol of targeted cells without the associated adverse effects. Our group recently reported a very effective and safe hybrid nanoparticle delivery system composing human IgG and poloxamer-188 for siRNA delivery to cancer cells. However, these nanoparticles need to be optimized in terms of particle size, loading capacity and encapsulation efficiency. In the present study, we explored the effects of certain production parameters on particle size, loading capacity and encapsulation efficiency. Further, to make these nanoparticles more specific in their delivery of siRNA, we conjugated anti-NTSR1-mAb to the surface of these nanoparticles to target NTSR1-overexpressing cancer cells. The mechanism of siRNA release from these antiNTSR1-mAb functionalized nanoparticles was also elucidated. It was demonstrated that the concentration of human IgG in the starting nanoprecipitation medium and the rotation speed of the magnetic stirrer influenced the encapsulation efficiency, loading capacity and the size of the nanoparticles produced. We also successfully transformed these nanoparticles into actively targeted nanoparticles by functionalizing with anti-NTSR1-mAb to specifically target NTSR1-overexpressing cancer cells, hence able to avoid undesired accumulation in normal cells. The mechanism of siRNA release from these nanoparticles was elucidated to be by Fickian diffusion. Using flow cytometry and fluorescence microscopy, we were able to confirm the active involvement of NTSR1 in the uptake of these anti-NTSR1-mAb functionalized hybrid nanoparticles by lung adenocarcinoma cells. This hybrid nanoparticle delivery system can be used as a platform technology for intracellular delivery of siRNAs to NTSR1-overexpressing tumor cells.Keywords
Funding Information
- QED Grant 2014 (S1402)
This publication has 33 references indexed in Scilit:
- Investigation of the Stability and Cellular Uptake of Self-Associated Monoclonal Antibody (MAb) Nanoparticles by Non-Small Lung Cancer CellsMolecular Pharmaceutics, 2013
- Docetaxel immunonanocarriers as targeted delivery systems for HER2-positive tumor cells: preparation, characterization, and cytotoxicity studiesInternational Journal of Nanomedicine, 2011
- Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumabInternational Journal of Nanomedicine, 2011
- Neurotensin Receptor 1 Determines the Outcome of Non–Small Cell Lung CancerClinical Cancer Research, 2010
- The exploitation of differential endocytic pathways in normal and tumor cells in the selective targeting of nanoparticulate chemotherapeutic agentsBiomaterials, 2010
- Decoupling Internalization, Acidification and Phagosomal-Endosomal/lysosomal Fusion during Phagocytosis of InlA Coated Beads in Epithelial CellsPLOS ONE, 2009
- Development of Lipidoid–siRNA Formulations for Systemic Delivery to the LiverMolecular Therapy, 2009
- The effect of particle design on cellular internalization pathwaysProceedings of the National Academy of Sciences, 2008
- Microfabricated Particles for Engineered Drug Therapies: Elucidation into the Mechanisms of Cellular Internalization of PRINT ParticlesPharmaceutical Research, 2008
- Mechanism of sustained‐action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matricesJournal of Pharmaceutical Sciences, 1963